The FDA's April 1 letter requesting additional data from Eli Lilly on liver injury associated with its newly approved oral GLP-1 agonist Foundayo is far more than a routine regulatory footnote. While the original STAT News Pharmalittle roundup presents it alongside unrelated pharma litigation as daily industry tidbits, this coverage misses the larger pattern: intensifying questions about whether rapid approvals and massive real-world uptake of weight-loss GLP-1 drugs have outpaced credible long-term safety evidence. Foundayo's approval under the Commissioner's National Priority voucher program — designed to expedite drugs critical to public health — now requires post-marketing studies on cardiovascular events, delayed gastric emptying, and a dedicated milk-only lactation trial in breastfeeding women using validated assays. These mandates expose critical pre-approval blind spots.

Contextualizing this requires examining the broader GLP-1 landscape. Eli Lilly's own SURMOUNT-1 trial (NEJM, 2022; double-blind RCT, n=2,539 adults with obesity, 72-week duration, industry-funded with clear conflicts of interest) demonstrated substantial weight loss with tirzepatide but explicitly noted limitations in detecting rare adverse events like hepatotoxicity due to exclusion criteria and relatively short follow-up. Similarly, the SELECT trial for semaglutide (NEJM, 2023; large RCT, n=17,604 participants with overweight/obesity and established CVD, median follow-up 39.8 months, Novo Nordisk sponsored) showed cardiovascular benefits yet relied on a population not fully representative of the millions now using these drugs off-label or for general weight management.

What original coverage consistently misses is the accumulating signal from independent observational research. A 2024 JAMA Internal Medicine retrospective cohort study (observational, n=1.4 million adults initiating GLP-1RAs or SGLT2 inhibitors using claims data, minimal industry funding) identified elevated risks of gastroparesis and biliary disease compared to other antidiabetic agents. This aligns with FAERS reports and emerging litigation over severe gastric paralysis — risks the FDA is now formally requiring Foundayo to study. The original STAT piece fails to connect these dots or note how accelerated pathways may have minimized scrutiny of liver enzyme elevations observed in earlier phase trials of oral GLP-1 candidates.

The lactation study requirement highlights another under-discussed gap. Peer-reviewed evidence here is sparse: a small 2023 observational pharmacokinetic study in Breastfeeding Medicine (n=14 lactating women, no conflicts declared) on related compounds detected low-level transfer into breast milk but cautioned that larger, controlled trials were essential to assess infant exposure. With millions of reproductive-age individuals using these medications, the absence of robust data before widespread adoption reflects a troubling prioritization of speed over comprehensive risk characterization.

This episode fits a repeating pattern with blockbuster drugs — from early statins to COX-2 inhibitors — where initial enthusiasm, direct-to-consumer momentum, and industry-funded RCTs (often with sample sizes in the low thousands but high marketing budgets) precede refined understanding of real-world harms. Millions are now using GLP-1 drugs chronically; even uncommon adverse events (1 in 1,000) translate to thousands of affected patients. The FDA's actions suggest regulatory caution is increasing, yet questions remain about whether post-marketing requirements will be adequately powered or independently overseen.

Synthesizing these sources reveals that while GLP-1 drugs represent genuine progress for obesity and cardiometabolic health, the current evidence base — dominated by industry RCTs of moderate duration and observational data prone to confounding — leaves critical uncertainties. The Foundayo letter should prompt deeper investment in independent, longer-term studies that include diverse populations excluded from pre-approval trials. Until then, clinicians must temper enthusiasm with transparent risk discussions, and regulators should reconsider whether national priority fast-tracking appropriately balances innovation against public safety when millions of healthy users are involved.